Publication:

Effect of gliclazide on cardiovascular risk factors involved in split-dose streptozotocin induced neonatal rat model: a chronic study

Background The present study aimed at evaluating the effect of gliclazide on cardiovascular risk factors involved in type 2 diabetes mellitus using n-STZ rat model on a long term basis.

Methods The diabetic model was developed using a split dose of streptozotocin (50 mg/kg) intraperitoneally on 2nd and 3rd postnatal days. The diabetic rats were treated orally with gliclazide suspension at the dose of 10 mg/kg for 90 days. Cardiovascular risk factors such as systolic blood pressure, heart rate, lipid profile, creatine kinase and lactate dehydrogenase were evaluated at regular intervals along with fasting blood glucose (FBG) and oral glucose tolerance test.

Results Gliclazide did not alter FBG however improved the impaired glucose tolerance. The gliclazide treated rats did not develop hypertension and there was a significant difference (p<0.001) at the end of treatment when compared to the diabetic group which could be due to free radical scavenging property of gliclazide. Gliclazide treatment in n-STZ model was found to be effective in preventing hypertension, creatine kinase and lactate dehydrogenase activity. Also gliclazide was found to have beneficial effects on the impaired glucose tolerance, dyslipidaemia, adiposity index and total fat pad weight.

Conclusions To improve and prevent the cardiovascular risk factors involved in Type II diabetic patients, gliclazide could be clinically beneficial.